About SCP

Founded: 2010
Employees: 132
CEO: Piotr Garstecki
WebsiteView website: www.scopefluidics.com

Scope Fluidics S.A., a biotechnology company, designs and develops projects based on microfluidic technologies in medical diagnostics and healthcare in Poland. The company offers BacterOMIC, an antibiotic susceptibility testing. Scope Fluidics S.A. was founded in 2010 and is based in Warsaw, Poland.

Recent SCP News & Updates

New Risk • May 11

New minor risk - Market cap size

The company's market capitalization is less than US$100m. Market cap: zł358.0m (US$99.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (zł100k revenue, or US$28k). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (zł358.0m market cap, or US$99.5m).

Recent updates

No updates

Scope Fluidics S.A. Stock Price

SCP Share Price Performance

SCP Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

Scope Fluidics S.A. Key Details

About SCP

Recent SCP News & Updates

First quarter 2026 earnings released: zł4.25 loss per share (vs zł4.04 loss in 1Q 2025)

New minor risk - Market cap size

We're Hopeful That Scope Fluidics (WSE:SCP) Will Use Its Cash Wisely

Recent updates

Scope Fluidics S.A. Competitors

NEUCA

Synektik Spólka Akcyjna

Voxel

Medinice